Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. (Q38175493)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

systemic lupus erythematosus

4 March 2020

main subject

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Zozik Fattah

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

English

0 references

publication date

6 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

4 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

311-326

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

Lupus erythematosus in the 1980s: a survey of 570 patients

4 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

The central and multiple roles of B cells in lupus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Taming lupus-a new understanding of pathogenesis is leading to clinical advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Treatment of systemic lupus erythematosus with epratuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Defective B cell tolerance checkpoints in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

A checkpoint for autoreactivity in human IgM+ memory B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

B-cell targeted treatments for lupus: the journey counts as much as the destination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Rituximab: a promising therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Ocrelizumab: a step forward in the evolution of B-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

BAFF, APRIL and their receptors: structure, function and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Peptide-based approaches to treat lupus and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Novel treatments for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-gamma and anti-double-stranded DNA antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Lupus: novel therapies in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Type I interferon correlates with serological and clinical manifestations of SLE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

B cell biomarkers of rituximab responses in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.871256

10.1517/14712598.2014.871256

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387632%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference